{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:29:01Z","timestamp":1787153341953,"version":"build-2736575974"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n Rosacea is a chronic inflammatory cutaneous disorder characterized by persistent erythema and vascular dysregulation. While paroxetine has shown clinical efficacy in reducing these symptoms, the systemic molecular mechanisms underlying its therapeutic response remain poorly characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate systemic proteomic alterations and identify potential predictive biomarkers in patients with refractory erythematous rosacea following paroxetine treatment.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective plasma proteomic analysis was nested within a multicenter, randomized, double-blind, placebo-controlled clinical trial (Prospective Rosacea Refractory Erythema Randomized Clinical Trial [PRRERCT]). Participants included patients aged 18 to 65 years with refractory rosacea (Clinician\u2019s Erythema Assessment [CEA] score \u22653). Plasma samples were collected at baseline and after 12 weeks of treatment. The data for this study were analyzed between September 2025 and November 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants received oral paroxetine, 25 mg per day, for a 12-week treatment period.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Systemic protein expression profiles were analyzed using data-independent acquisition liquid chromatography-tandem mass spectrometry. Clinical response was evaluated using CEA and the Flushing Assessment Tool. Correlations between proteomic changes and clinical improvements were assessed, and predictive biomarkers were identified using receiver operating characteristic curve analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 24 participants (mean [SD] age, 35 [11] years; 24 [100%] female), paroxetine treatment significantly reduced mean (SD) CEA scores from 3.1 (0.3) to 2.3 (0.7) and Flushing Assessment Tool scores from 3.1 (0.6) to 2.0 (0.9) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Exploratory proteomic analysis revealed 497 candidate differentially expressed proteins after treatment. Downregulated proteins showed preliminary enrichment in pathways related to immune response activation, insulin receptor signaling, and neuronal remodeling. A subset of 98 reversed-response proteins was observed, primarily linked to synaptic vesicle cycles and vascular smooth muscle contraction. Proteomic alterations were associated with clinical improvement (65 proteins for erythema; 73 for flushing). Candidate biomarkers, notably OLFML3 (area under the receiver operating characteristic curve [AUC], 0.87 [95% CI, 0.70-1.00]) and IGFBP2 (AUC, 0.80 [95% CI 0.55-1.00]), demonstrated high predictive value for clinical response.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of a randomized clinical trial, paroxetine treatment was associated with modulation of systemic neuro-vascular-immune networks in patients with rosacea. These exploratory findings provide preliminary mechanistic clues regarding the possible disease-modifying potential of paroxetine and point to circulating protein signatures that may facilitate personalized therapeutic strategies for rosacea management.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n Chinese Clinical Trial Registry Identifier:\n ChiCTR2000031479<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.1437","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:30:41Z","timestamp":1781710241000},"page":"804","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Proteomic Alterations and Predictive Biomarkers of Paroxetine Response in Refractory Rosacea"],"prefix":"10.1001","volume":"162","author":[{"given":"Ben","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiya","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, ChinaA"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"FuRong Laboratory, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi260017r1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/12034754241229365","article-title":"Rosacea: pathogenesis and therapeutic correlates.","volume":"28","author":"Geng","year":"2024","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"doi260017r2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","article-title":"Rosacea: new concepts in classification and treatment.","volume":"22","author":"van Zuuren","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"doi260017r3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367994","article-title":"Signaling pathways and targeted therapy for rosacea.","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"doi260017r4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403798","article-title":"Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.","volume":"15","author":"Tu","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"doi260017r5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/jdv.19732","article-title":"Biomarkers in rosacea: a systematic review.","volume":"38","author":"Geng","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi260017r6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/ced.12630","article-title":"Neurogenic rosacea: an uncommon and poorly recognized entity?","volume":"40","author":"Parkins","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"21","key":"doi260017r7","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","article-title":"Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.","volume":"289","author":"Stearns","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"doi260017r8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jaad.2023.01.044","article-title":"Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial.","volume":"88","author":"Wang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"doi260017r9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-0716-1024-4","article-title":"Quantitative mass spectrometry-based proteomics: an overview.","volume":"2228","author":"Rozanova","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"1","key":"doi260017r10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaad.2025.08.014","article-title":"Proteomic profiling reveals distinct inflammatory and neurogenic endotypes in rosacea.","volume":"94","author":"Huang","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi260017r11","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22464","article-title":"Paroxetine modulates immune responses by activating a JAK2\/STAT3 signaling pathway.","volume":"34","author":"Kabiri","year":"2020","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"doi260017r12","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14988","article-title":"Fluoxetine exerts anti-inflammatory effects on human epidermal keratinocytes and suppresses their endothelin release.","volume":"33","author":"T\u00f3th","year":"2024","journal-title":"Exp Dermatol"},{"issue":"4","key":"doi260017r13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s12640-021-00367-5","article-title":"Immune-regulatory and molecular effects of antidepressants on the inflamed human keratinocyte HaCaT cell line.","volume":"39","author":"Curzytek","year":"2021","journal-title":"Neurotox Res"},{"issue":"14","key":"doi260017r14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/CM9.0000000000000309","article-title":"Olfactomedin-like 3: possible functions in embryonic development and tumorigenesis.","volume":"132","author":"Jin","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"doi260017r15","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1096\/fj.202000751RR","article-title":"Olfactomedin-like 3 promotes PDGF-dependent pericyte proliferation and migration during embryonic blood vessel formation.","volume":"34","author":"Imhof","year":"2020","journal-title":"FASEB J"},{"key":"doi260017r16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1073320","article-title":"Matricellular proteins in cutaneous wound healing.","volume":"10","author":"C\u00e1rdenas-Le\u00f3n","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"doi260017r17","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20220052","article-title":"OLFML3, as a potential predictor of prognosis and therapeutic target for glioma, is closely related to immune cell infiltration.","volume":"4","author":"Qu","year":"2023","journal-title":"View (Beijing)"},{"key":"doi260017r18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1292722","article-title":"Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.","volume":"10","author":"Fisher","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"doi260017r19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.7150\/ijbs.103859","article-title":"OLFML3 promotes IRG1 mitochondrial localization and modulates mitochondrial function in macrophages.","volume":"21","author":"Yu","year":"2025","journal-title":"Int J Biol Sci"},{"key":"doi260017r20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fendo.2018.00499","article-title":"Insulin-like growth factor binding proteins in autoimmune diseases.","volume":"9","author":"Ding","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"doi260017r21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","article-title":"IGFBP2: integrative hub of developmental and oncogenic signaling network.","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene"},{"key":"doi260017r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156750","article-title":"The critical roles of IGFs in immune modulation and inflammation.","volume":"183","author":"Wang","year":"2024","journal-title":"Cytokine"},{"key":"doi260017r23","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9223883","article-title":"Elevated serum IGFBP-2 and CTGF levels are associated with disease activity in patients with dermatomyositis.","volume":"2022","author":"Yang","year":"2022","journal-title":"Dis Markers"},{"issue":"1","key":"doi260017r24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ghir.2014.11.001","article-title":"Effects of IGFBP-1 and IGFBP-2 and their fragments on migration and IGF-induced proliferation of human dermal fibroblasts.","volume":"25","author":"Brandt","year":"2015","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"doi260017r25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/08977194.2023.2259497","article-title":"Knock-down of IGFBP2 ameliorates lung fibrosis and inflammation in rats with severe pneumonia through STAT3 pathway.","volume":"41","author":"Wang","year":"2023","journal-title":"Growth Factors"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2849949\/jamadermatology_wang_2026_oi_260017_1786734785.73517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:00:25Z","timestamp":1787151625000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2849949"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1437","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}